BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Williams JG, Alam MF, Alrubaiy L, Clement C, Cohen D, Grey M, Hilton M, Hutchings HA, Longo M, Morgan JM, Rapport FL, Seagrove AC, Watkins A. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). Health Technol Assess 2016;20:1-320. [PMID: 27329657 DOI: 10.3310/hta20440] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR. Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. J Crohns Colitis 2018;12:289-97. [PMID: 29121178 DOI: 10.1093/ecco-jcc/jjx146] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
2 Bernstein CN, Kornbluth A. Yes, We Are Still Talking about Cylosporin vs. Infliximab in Steroid Resistant Acute Severe Ulcerative Colitis. Am J Gastroenterol 2017;112:1719-21. [PMID: 29109492 DOI: 10.1038/ajg.2017.282] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Szemes K, Soós A, Hegyi P, Farkas N, Erős A, Erőss B, Mezősi E, Szakács Z, Márta K, Sarlós P. Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis. Front Med (Lausanne) 2019;6:338. [PMID: 32039218 DOI: 10.3389/fmed.2019.00338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
4 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
5 Touray MML. Estimation of Quality-adjusted Life Years alongside clinical trials: the impact of 'time-effects' on trial results. J Pharm Health Serv Res 2018;9:109-14. [PMID: 29861785 DOI: 10.1111/jphs.12218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Clement C, Rapport F, Seagrove A, Alrubaiy L, Williams J. Healthcare professionals' views of the use and administration of two salvage therapy drugs for acute ulcerative colitis: a nested qualitative study within the CONSTRUCT trial. BMJ Open 2017;7:e014512. [PMID: 28399515 DOI: 10.1136/bmjopen-2016-014512] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018;32-33:59-69. [PMID: 30060940 DOI: 10.1016/j.bpg.2018.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
8 Rapport F, Clement C, Seagrove AC, Alrubaiy L, Hutchings HA, Williams JG. Patient views about the impact of ulcerative colitis and its management with drug treatment and surgery: a nested qualitative study within the CONSTRUCT trial. BMC Gastroenterol 2019;19:166. [PMID: 31615445 DOI: 10.1186/s12876-019-1085-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Argollo MC, Kotze PG, Spinelli A, Gomes TN, Danese S. The impact of biologics in surgical outcomes in ulcerative colitis. Best Practice & Research Clinical Gastroenterology 2018;32-33:79-87. [DOI: 10.1016/j.bpg.2018.05.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
10 Qian Y, Walters SJ, Jacques R, Flight L. Comprehensive review of statistical methods for analysing patient-reported outcomes (PROs) used as primary outcomes in randomised controlled trials (RCTs) published by the UK's Health Technology Assessment (HTA) journal (1997-2020). BMJ Open 2021;11:e051673. [PMID: 34489292 DOI: 10.1136/bmjopen-2021-051673] [Reference Citation Analysis]
11 Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Rodríguez-Moranta F, Márquez L, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, LLaó J, Gisbert JP, Aguas M, Arias L, Rodríguez-Lago I, Muñoz C, Alcaide N, Calvet X, Rodríguez C, Montoro MA, García S, De Castro ML, Piqueras M, Pareja L, Ribes J, Panés J, Esteve M; ENEIDA registry of GETECCU. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry. Am J Gastroenterol 2018;113:1009-16. [PMID: 29713028 DOI: 10.1038/s41395-018-0057-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
12 Worley G, Almoudaris A, Bassett P, Segal J, Akbar A, Ghosh S, Aylin P, Faiz O. Colectomy rates for ulcerative colitis in England 2003-2016. Aliment Pharmacol Ther 2021;53:484-98. [DOI: 10.1111/apt.16202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ogino T, Mizushima T, Matsuda C, Mori M, Doki Y. Essential updates 2018/2019: Colorectal (benign): Recent updates (2018-2019) in the surgical treatment of benign colorectal diseases. Ann Gastroenterol Surg 2020;4:30-8. [PMID: 32021956 DOI: 10.1002/ags3.12304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
14 Hutchings HA, Alrubiay L, Watkins A, Cheung WY, Seagrove AC, Williams JG. Validation of the Crohn's and Ulcerative Colitis questionnaire in patients with acute severe ulcerative colitis. United European Gastroenterol J 2017;5:571-8. [PMID: 28588889 DOI: 10.1177/2050640616671627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
15 Jairath V, Mcdonald JW, Feagan BG. Ulcerative Colitis. In: Feagan BG, Kahrilas PJ, Jalan R, Mcdonald JWD, editors. Evidence-based Gastroenterology and Hepatology 4e. Chichester: John Wiley & Sons, Ltd; 2019. pp. 173-86. [DOI: 10.1002/9781119211419.ch11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Peñalva M, Cañas-Ventura A, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, Garcia-Planella E, Chaparro M, Aguas M, Gento E, Muñoz F, Aguirresarobe M, Muñoz C, Fernández L, Calvet X, Jiménez CE, Montoro MA, Mir A, De Castro ML, García-Sepulcre MF, Bermejo F, Panés J, Esteve M. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study. Am J Gastroenterol 2017;112:1709-18. [PMID: 28675163 DOI: 10.1038/ajg.2017.180] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
17 Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45:617-630. [PMID: 28074618 DOI: 10.1111/apt.13913] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 8.6] [Reference Citation Analysis]
18 Clement C, Edwards SL, Rapport F, Russell IT, Hutchings HA. Exploring qualitative methods reported in registered trials and their yields (EQUITY): systematic review. Trials 2018;19:589. [PMID: 30373646 DOI: 10.1186/s13063-018-2983-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
19 Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9:65-72. [PMID: 29387331 DOI: 10.1177/2040622317742095] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
20 Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
21 Norton C, Syred J, Kerry S, Artom M, Sweeney L, Hart A, Czuber-Dochan W, Taylor SJC, Mihaylova B, Roukas C, Aziz Q, Miller L, Pollok R, Saxena S, Stagg I, Terry H, Zenasni Z, Dibley L, Moss-Morris R. Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. Trials 2021;22:516. [PMID: 34344432 DOI: 10.1186/s13063-021-05466-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos KH, Croft N, Navas-López VM, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. [PMID: 30044358 DOI: 10.1097/MPG.0000000000002036] [Cited by in Crossref: 64] [Cited by in F6Publishing: 21] [Article Influence: 21.3] [Reference Citation Analysis]
23 Jairath V. Hyperbaric Oxygen for Hospitalized patients with Ulcerative Colitis. American Journal of Gastroenterology 2018;113:1432-4. [DOI: 10.1038/s41395-018-0224-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Armuzzi A, Bortoli A, Castiglione F, Contaldo A, Daperno M, D'Incà R, Labarile N, Mazzuoli S, Onali S, Milla M, Orlando A, Principi M, Pugliese D, Renna S, Rizzello F, Scribano ML, Todeschini A; Italian Group for the Study of Inflammatory Bowel Disease Working Group. Female reproductive health and inflammatory bowel disease: A practice-based review. Dig Liver Dis 2021:S1590-8658(21)00271-1. [PMID: 34120858 DOI: 10.1016/j.dld.2021.05.020] [Reference Citation Analysis]
25 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Beaugerie L, Ricart E, Dewit O, Lopez-sanroman A, Fumery M, Carbonnel F, Buisson A, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Peyrin-biroulet L, Mary J. Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. Clinical Gastroenterology and Hepatology 2021;19:1180-1188.e4. [DOI: 10.1016/j.cgh.2020.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
26 Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7:77-90. [PMID: 30976420 DOI: 10.1093/gastro/goz004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
27 Walsh A, Matini L, Hinds C, Sexton V, Brain O, Keshav S, Geddes J, Goodwin G, Collins G, Travis S, Peters M. Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis. Intest Res 2019;17:365-74. [PMID: 31146510 DOI: 10.5217/ir.2018.00173] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, Gordon JN, Hawthorne AB, Hilton M, Hutchings HA, Jawhari AU, Longo M, Mansfield J, Morgan JM, Rapport F, Seagrove AC, Sebastian S, Shaw I, Travis SP, Watkins A. Infliximab vs ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2016;1:15-24. [PMID: 27595142 DOI: 10.1016/s2468-1253(16)30003-6] [Cited by in Crossref: 108] [Cited by in F6Publishing: 36] [Article Influence: 27.0] [Reference Citation Analysis]
29 Jean L, Audrey M, Beauchemin C, Consortium OBOTI. Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review. Can J Gastroenterol Hepatol 2018;2018:7439730. [PMID: 30009158 DOI: 10.1155/2018/7439730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
30 Alrubaiy L, Arnott I, Protheroe A, Roughton M, Driscoll R, Williams JG. Inflammatory bowel disease in the UK: is quality of care improving? Frontline Gastroenterol 2013;4:296-301. [PMID: 28839740 DOI: 10.1136/flgastro-2013-100333] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
31 Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20:1-326. [PMID: 27220829 DOI: 10.3310/hta20390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
32 Dignass A, Waller J, Cappelleri JC, Modesto I, Kisser A, Dietz L, DiBonaventura M, Wood R, May M, Libutzki B, Bargo D. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. J Med Econ 2020;23:415-27. [PMID: 31858853 DOI: 10.1080/13696998.2019.1707210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zhao HN, Jiang M, Sun MJ, Dai C. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis. Saudi J Gastroenterol 2021;27:191-200. [PMID: 34380865 DOI: 10.4103/sjg.sjg_145_21] [Reference Citation Analysis]